Nyhet -

Integrum’s bone-anchored implant helps American war veterans

The Gothenburg-based company Integrum has developed the OPRATM Implant System, which instead of being attached with a socket around the amputated limb is attached directly to the skeleton. The system is now being implemented in a treatment program for US veterans as the company aims to change the standard of care globally.

In the 1960s, Per-Ingvar Brånemark research led to a billion-dollar industry by transforming the lives of people without teeth. His son, Rickard Brånemark, is the founder and CEO of Integrum, a company that is well on its way of doing the same for people who have lost a limb. The technology to grow the implant into the skeleton is basically the same, but it has taken decades of development to enable the same technology for larger implants such as bone and arm replacements.

“Today's socket prostheses have fundamental limitations and many users choose to live without a prosthesis. Our system completely changes the view of what standard of living and functionality can be achieved after an amputation,” says Rickard Brånemark, who in addition to being the founder and CEO of Integrum is an internationally recognized surgeon and researcher.

The aim is for OPRATM Implant System to become the new standard treatment after amputation. Since receiving Premarket Approval in the United States in 2020, Integrum has focused on expansion in the US. An important part of this is the partnership that Integrum has established with Veterans Affairs, the organization responsible for the care of veterans. An OPRATM treatment program for amputee veterans was recently launched and the program is planned to expand in the coming years.

A company of great interest

During the summer of 2021, a share issue was made to raise capital for future development of integrated prostheses. For the first time, Integrum has brought in several institutional investors to invest in the company’s development.

“From a Gothenburg perspective, we see that the interest in our business is great, as the Stena sphere has stepped in with capital to finance our research and growth for example. This, and the fact that we in spring 2023 are moving to Gothenburg’s new arena for innovation within Life Science, GoCo Health Innovation City, underlines that we are a part of Gothenburg’s legacy as a leading Life Science region”, says Rickard Brånemark.

Roots, heart, and soul in Sweden

Integrum is in the middle of a major expansion and Rickard Brånemark explains:

“To develop our main business, we collaborate with Chalmers University of Technology, Sahlgrenska Bionic Center, US Department of Defense and MIT - Massachusetts Institute of Technology. In addition to that, we have made around 20 recruitments over the last 12 months. It takes time to establish ground-breaking treatments like ours, but when it finally happens the speed accelerates. That is why we currently experience the most expansive phase of the company’s history so far.”

Rickard Brånemark reveals that for a company that has its roots, heart, and soul in Sweden, Europe will always be important, even though right now most of the focus is on the US expansion.

Relaterade länkar

Ämnen

  • Ekonomi, finans

Kategorier

  • gothenburg life science

Regioner

  • Västra Götaland

Kontakter

Relaterat innehåll

  • Specialist care with a holistic approach

    Atleva Specialistvård AB is a Swedish healthcare provider specialising in hand surgery, foot surgery and pain care, with focuson long-term non-malignant pain. Within the organisation there is also a clinic specialising in the prevention of ill health, acting as a health care partner to anyone wanting to make good health a main priority.
    Atleva Specialistvård was founded in 2008 by doctors who

  • Founding Partner Mölnlycke Health Care will move to GoCo in 2024

    Mölnlycke Health Care stands for innovation and quality. This is also a strongly contributing reason why all Gothenburg-based operations within Mölnlycke will move to GoCo Health Innovation City at the end of 2024.
    All stakeholders in medicine and health technology have a comprehensive responsibility to help healthcare reach the next level with better products and more effective solutions.

  • A new giant is born with GoCo Health Innovation City

    Within a few years, between 8,000 and 10,000 jobs will be created in the GoCo Health Innovation City.
    Just like the BioVentureHub and the innovation environment there, GoCo Health Innovation City has been created on the initiative of AstraZeneca.
    In the beginning there was a giant
    It started with the pharmaceutical giant, AstraZeneca looking to sell some of their land connecting to thei

  • Kromnigon takes multi-colour microscopy to a new level

    A company based on innovative thinking can be a real game-changer. The founders of Kromnigon have worked with existing technologies and made important upgrades and modifications to create all new possibilities in multi-colour microscopy. This will for example benefit the development of immunotherapy treatments.
    Microscopy is a proven technique that has been around for a long time due to its ab

  • The value of a Quality Target Product Profile in early development

    Clinical trials make up a substantial portion of the overall drug development costs and pharmaceutical companies are intensely focused on ensuring that the trial is well designed and developed. The development of the actual drug product, the Chemistry, Manufacturing and Controls (CMC) section of Investigational Medicinal Products Dossiers (IMPDs) or Investigational New Drug (IND) applications, is

  • From early device development to validated production with AutomationsPartner

    AutomationsPartner is one of very few companies in Sweden specializing in the development of automated assembly systems for customers only within medical technology manufacturing.
    AutomationsPartner supports customers in developing their business and their products by building highly efficient automated assembly lines primarily for medical devices.
    From development to manufacturing
    The